Ultragenyx Pharmaceutical reported $-193567000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Kyowa Hakko Kirin JPY 12.82B 5.39B Jun/2025
MacroGenics USD -36760000 20.17M Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025